Alumis' LUMUS Phase 2b Trial Misses Primary Endpoint in SLE, But IFNGS-High Subgroup Shows Compelling Efficacy
ALMS has more than doubled off its 52-week low of $3.76.
Summary
Alumis' Phase 2b LUMUS trial in SLE missed its primary endpoint overall, but showed strong efficacy in the IFNGS-high subgroup, supporting a Phase 3 path forward. Safety was clean, and the company plans End of Phase 2 meetings with regulators.
Key Events · Product Development and Regulatory · ALMS
-
LUMUS Trial Misses Primary Endpoint
Envudeucitinib failed to meet the primary endpoint (BICLA at Week 48) in the overall SLE population, with p-values of 0.37–0.50 across all three doses.
-
IFNGS-High Subgroup Shows Robust Efficacy
In prespecified IFNGS-high patients, BICLA response rates were 40.7% (20mg QD), 49.5% (20mg BID), and 52.6% (40mg BID) vs 28.6% placebo, with treatment differences of 11.6–24.0 percentage points.
-
Clean Safety Profile
No MACE, extended MACE, or malignancies reported; TEAEs, grade ≥3 TEAEs, and SAEs were lower on active treatment than placebo.
-
Regulatory Path Forward
Company plans End of Phase 2 meetings with FDA and EMA to discuss Phase 3 design enriched for IFNGS-high patients, with ongoing partnering discussions.
Analysis · ALMS · Life Sciences
The Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus failed to meet its primary endpoint (BICLA at Week 48) in the overall population, with p-values of 0.37–0.50 across doses. However, the prespecified IFNGS-high subgroup — representing roughly 60% of enrolled patients and the majority of moderate-to-severe SLE cases — showed robust, dose-dependent responses: BICLA treatment differences of 11.6 to 24.0 percentage points versus placebo, with the 40mg BID dose achieving a 52.6% response rate versus 28.6% for placebo. Safety was clean with no new signals. The company will pursue End of Phase 2 meetings with FDA and EMA to design a Phase 3 program enriched for IFNGS-high patients. This is a pivotal readout for a $2.9B market-cap biotech: the overall miss is a setback for the broad SLE indication, but the subgroup data provide a credible path forward and de-risk the mechanism. The stock's reaction will hinge on whether investors view the IFNGS-high signal as sufficient for regulatory success.
How filings like this one have moved
In the 30 days to Sep 11, 2026, 41.8% of the 507 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALMS was trading at $22.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $3.76 to $31.35. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.